Core Insights - Polaryx Therapeutics has announced the commencement of trading of its common stock on the Nasdaq Capital Market under the ticker symbol "PLYX" [1][2] - The listing is viewed as a significant milestone for the company, marking a new phase in its development and potential opportunities in the rare lysosomal storage disorders (LSDs) market [2] - The company is set to launch the SOTERIA trial in the first half of 2026, which will evaluate the safety and efficacy of its lead drug candidate, PLX-200, across multiple LSD indications [2][3] Company Overview - Polaryx Therapeutics is a clinical-stage biotechnology company focused on developing therapies for rare orphan lysosomal storage disorders [4] - Founded in 2014, the company aims to provide safe and effective treatments that address the underlying pathophysiology of these diseases [4] - The lead product candidate, PLX-200, targets several LSDs and is part of a broader strategy that includes small molecule therapies and gene therapy [4] SOTERIA Trial Details - The SOTERIA trial is a Phase 2, open-label, single-arm study designed to assess the safety, tolerability, and clinical activity of PLX-200 in patients with CLN2, CLN3, Krabbe disease, and Sandhoff disease [3] - The trial is expected to include sites in the United States, Europe, and Asia, and aims to validate PLX-200's preclinical science while gathering critical data for future development [3] - A natural history study will serve as a control arm for the CLN2 and CLN3 cohorts, providing comparative data against PLX-200's treated arm [3]